Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries

This study is testing whether mosunetuzumab — a bispecific antibody that helps your immune system recognize and destroy lymphoma cells — can effectively treat follicular lymphoma that came back or stopped responding within 24 months of initial treatment. This early relapse is considered a higher-risk situation. **You may be eligible if...** - You are 18 or older - You have follicular lymphoma (grade 1–3a) that has relapsed or progressed within 24 months of starting your first treatment, OR your lymphoma did not respond to first-line treatment - Your first treatment included a combination involving an anti-CD20 drug (like rituximab) and chemotherapy - You require further treatment based on your doctor's assessment **You may NOT be eligible if...** - Your follicular lymphoma has transformed into a more aggressive type - You have previously received CAR-T therapy - You have active serious infections or significant organ problems - You are pregnant or breastfeeding - You have other active cancers Talk to your doctor to see if this trial is right for you.